The main point
Growth hormone (GH) is made by the pituitary gland, and it can be nudged in two ways: by a signal from the hormone that releases GH (GHRH), or by a signal at the ghrelin receptor. Sermorelin and CJC-1295 work by the first route, ipamorelin and hexarelin by the second, and the tablet ibutamoren (MK-677) is their neighbour in how it works. In studies all of them raised a person's own GH, and with CJC-1295 and ibutamoren insulin-like growth factor 1 (IGF-1) rose after it. Sermorelin is the best studied, in children with GH deficiency: growth rate rose from 4.1 to 7.2 cm a year over 12 months (86 children, no control group). In adults the results are more modest: with ibutamoren lean body mass rose by 1.1 kg over a year (65 people), and strength did not change. The combination of CJC-1295 and ipamorelin has not been tested in published work. On peptides as a class: MOTS-c: a peptide that responds to exercise.
| Substance | What it does | What studies showed | Who it is discussed for |
|---|---|---|---|
| Sermorelin (Geref) | GHRH analogue: boosts the body's own GH release | Children with GH deficiency (86): growth 4.1 → 7.2 cm/year over 12 months; adults 55–71 (19): by week 16 IGF-1 was close to baseline again, sleep unchanged | Children with GH deficiency (was used), diagnostic test |
| CJC-1295 | Long-acting GHRH analogue, half-life 5.8–8.1 days | GH 2–10 times higher for 6 days or more, IGF-1 1.5–3 times higher for 9–11 days; pulsing preserved | Investigational drug, did not reach the clinic |
| Ipamorelin | Ghrelin receptor agonist: one short GH release | GH peak at 40 minutes; in bowel paralysis 25.3 versus 32.6 h, p = 0.15, difference not significant (114) | Investigational drug |
| Hexarelin | Ghrelin receptor agonist, also acts on the heart | Left ventricular ejection fraction 64.0 → 70.7% after one injection (7 men); over 16 weeks the GH response fell by about 45% (12 people) and returned 4 weeks after stopping | Investigational drug |
| Ibutamoren (MK-677), tablet | Ghrelin receptor agonist, taken by mouth | IGF-1 1.5 times higher, lean mass +1.1 versus −0.5 kg; glucose +0.3 mmol/L (5 mg/dL) (65) | Investigational drug |
How the body releases growth hormone itself
The pituitary releases GH in pulses, not in an even stream, and the substances described here strengthen these pulses rather than replace them. There are two entrances for this.
The first entrance: GHRH from the hypothalamus acts on its own receptor in the pituitary. Sermorelin (the first 29 amino acids of GHRH) is called in a review the shortest synthetic peptide with the full biological activity of GHRH (Prakash A BioDrugs 1999. PMID 18031173). CJC-1295 is also a GHRH analogue, but a long-acting one: it binds to albumin and stays in the blood for days (Teichman SL J Clin Endocrinol Metab 2006. PMID 16352683).
The second entrance: the ghrelin receptor in the pituitary and hypothalamus; ipamorelin, hexarelin and ibutamoren act through it (Nass R Ann Intern Med 2008. PMID 18981485). Hexarelin, unlike GHRH, also raises prolactin and ACTH with cortisol (Arvat E Eur J Endocrinol 1997. PMID 9437229).
The shared condition: both routes work when the pituitary is intact. In adults with severe GH deficiency the GH peak on hexarelin was 1.9 µg/L (ng/mL) versus 45.7 µg/L (ng/mL) in healthy people (7 and 9 people; Bisi G Eur J Pharmacol 1999. PMID 10528131).
Sermorelin: the most data in children
For many years sermorelin was produced for children with delayed growth. According to a review, bedtime subcutaneous injections helped some prepubertal children with idiopathic GH deficiency, the gain in growth rate lasted 12 months, in a few up to 36, and the effect on final height has not been determined. The most often noted effects were transient facial flushing and pain at the injection site (Prakash A BioDrugs 1999. PMID 18031173).
In an open study, in 86 of 110 prepubertal children with GH deficiency growth rate rose from 4.1 ± 0.9 to 8.0 ± 1.5 cm/year by month 6 and was 7.2 ± 1.3 cm/year by month 12; 74% of children had a good response by month 6. Fasting glucose did not change, and there was no excess IGF-1 production (Thorner M J Clin Endocrinol Metab 1996. PMID 8772599; the study has no control group).
In adults sermorelin was studied in small groups. In 19 people aged 55–71 (10 women and 9 men), after 16 weeks of bedtime injections night-time GH was higher, IGF-1 rose by week 2 and held until week 12, and by week 16 came close to baseline again. Lean body mass, insulin sensitivity and well-being improved only in men; fasting glucose and insulin did not change, and sleep quality did not change in anyone (Khorram O J Clin Endocrinol Metab 1997. PMID 9141536; 4 weeks of placebo first, then the drug, no parallel control).
In 11 healthy men aged 64–76, 6 weeks of single bedtime injections raised night-time GH, but IGF-1, weight, body composition, glucose and lipids did not change; 2 of 6 strength tests improved. The authors consider single bedtime doses less effective than several injections a day (Vittone J Metabolism 1997. PMID 9005976; no control group).
According to an editorial, the manufacturer withdrew sermorelin from the market for a commercial reason: the drug could not compete with recombinant GH (Walker RF Clin Interv Aging 2006. PMID 18046908).
CJC-1295: a long signal for the pituitary
In two randomized double-blind studies in healthy people aged 21–61, a single subcutaneous injection of CJC-1295 raised average GH 2–10 times for 6 days or more, and average IGF-1 1.5–3 times for 9–11 days, depending on the dose. There were no serious adverse reactions (Teichman SL J Clin Endocrinol Metab 2006. PMID 16352683; the number of participants is not named in the abstract).
GH pulsing was preserved: a week after a single injection in healthy men aged 20–40, the frequency and amplitude of the peaks did not change, GH between peaks rose 7.5 times, average GH by 46% and IGF-1 by 45% (Ionescu M J Clin Endocrinol Metab 2006. PMID 17018654). These studies measured hormones, not well-being and body composition. By status, CJC-1295 is named as an unapproved synthetic analogue (Memdouh S Drug Test Anal 2021. PMID 34665524).
Ipamorelin: a short, quick release
In healthy men (8 people for each of five doses) ipamorelin caused one GH release with a peak after about 40 minutes and a return to baseline; the half-life was 2 hours (Gobburu JV Pharm Res 1999. PMID 10496658). This study measured GH after a single dose; IGF-1 was not measured.
Ipamorelin was also tested after bowel surgery: in 114 people in a double-blind placebo-controlled phase 2 study. The median time to first tolerated solid food was 25.3 hours on ipamorelin versus 32.6 hours on placebo, p = 0.15. The difference is not significant, and there were no significant differences in the other main measures. Adverse events: 87.5% versus 94.8% on placebo (Beck DE Int J Colorectal Dis 2014. PMID 25331030).
The combination of CJC-1295 and ipamorelin
The pairing looks logical: one signal through the GHRH receptor, the other through the ghrelin receptor. CJC-1295 was studied in healthy people by hormone measures, and ipamorelin by the GH release and in one clinical task. They have not been tested together in published work, so the sources have no figures on the action of the combination.
Hexarelin: hormones and the heart
In a single-dose experiment in 60 people (from children to 16 older people aged 66–81) hexarelin raised GH, prolactin, ACTH and cortisol. In older people the GH response was half as high: 951.1 versus 1829.7 µg·min/L (ng·min/mL) in young people, P < 0.005 (Arvat E Eur J Endocrinol 1997. PMID 9437229).
With long-term administration the response changes. In 12 healthy older people given subcutaneous injections twice a day, the area under the GH curve fell from 19.1 to 10.5 µg/L·h (ng/mL·h) by week 16, by about 45%, and 4 weeks after stopping returned to 19.4 µg/L·h (ng/mL·h). The weakening is partial and reversible (Rahim A Growth Horm IGF Res 1998. PMID 10990150). In an 8-day and a 15-day schedule (7 older people each) the GH response was preserved; in the second group IGF-1 rose slightly, from 141.6 ng/mL (18.5 nmol/L) to 156.0 ng/mL (20.4 nmol/L), P < 0.03, while prolactin and cortisol did not change (Ghigo E Eur J Endocrinol 1996. PMID 8921821).
After a single intravenous injection, the left ventricular ejection fraction (LVEF), that is the share of blood the heart pushes out per beat, rose in 7 healthy men from 64.0 to 70.7% (p < 0.03) and held for up to 60 minutes, while recombinant GH with the same GH rise did not change it: 62.4 and 62.1% (Bisi G J Endocrinol Invest 1999. PMID 10342360). In 5 people with ischemic cardiomyopathy LVEF rose from 22.6 to 26.2%, while in 8 with dilated cardiomyopathy there was no effect (Imazio M Eur J Heart Fail 2002. PMID 11959048). In 24 men with coronary heart disease during bypass surgery (group sizes are not given in the abstract) hexarelin within 10 minutes raised LVEF and cardiac output (P < 0.001) for up to 90 minutes, while GHRH, recombinant GH and placebo did not change hemodynamics (Broglio F Eur J Pharmacol 2002. PMID 12144941). All the data were obtained after a single dose in small groups.
Ibutamoren (MK-677): a neighbour in mechanism
Ibutamoren acts on the ghrelin receptor, but it is a tablet. In a two-year double-blind placebo-controlled study, 65 healthy people aged 60–81 completed the first year (43 on MK-677, 22 on placebo). Average daily GH rose 1.8 times, IGF-1 1.5 times; in 22 of 43 people IGF-1 stayed within the range of young adults. Lean body mass on MK-677 rose by 1.1 kg (0.7–1.5), on placebo it fell by 0.5 kg. Fat (visceral and total), strength and functional tests did not differ from placebo (Nass R Ann Intern Med 2008. PMID 18981485).
The price of the effect in the same study: fasting glucose rose by 0.3 mmol/L (5 mg/dL), glycated hemoglobin HbA1c by 0.2% versus a fall of 0.1% on placebo, insulin sensitivity fell, cortisol rose by 47 nmol/L (1.7 µg/dL), LDL fell by 0.14 mmol/L (5.4 mg/dL). Appetite rose in 67% versus 36% on placebo, swelling occurred in 44% versus 27% (p = 0.3, not significant).
In a study in 32 older people aged 64–81 (Chapman IM J Clin Endocrinol Metab 1996. PMID 8954023), in the 25 mg group over 4 weeks (the number of participants in the group is not given in the abstract) IGF-1 rose from 141 ng/mL (18.5 nmol/L) to 265 ng/mL (34.7 nmol/L), and fasting glucose from 5.4 to 6.8 mmol/L (from 97 to 122 mg/dL). In a 24-week study after hip fracture (123 people) IGF-1 rose by 51.4 ng/mL (6.7 nmol/L), most functional tests did not improve, and the study was stopped early because of a congestive heart failure signal in some participants (Adunsky A Arch Gerontol Geriatr 2011. PMID 21067829). On blood sugar: what helps with insulin resistance.
Safety: what is seen for each substance
Sermorelin: fasting glucose did not change (Thorner, Khorram); facial flushing, pain at the injection site and transient hyperlipidemia, that is a temporary rise of blood fats, were noted (Prakash, Khorram). CJC-1295: no serious adverse reactions were noted. Ipamorelin: adverse events 87.5% versus 94.8% on placebo.
Hexarelin: an acute rise of prolactin and cortisol after the dose, with no change over 8–15 days of use. Ibutamoren: a rise of glucose, HbA1c, cortisol and appetite, and a heart failure signal after hip fracture. These substances are prohibited in sport (Memdouh S Drug Test Anal 2021. PMID 34665524; Semenistaya E Drug Test Anal 2015. PMID 25869809). On cortisol: cortisol and the adrenal glands.
How they are used
Sermorelin in children with GH deficiency was given subcutaneously at bedtime. CJC-1295 in trials was given subcutaneously, once or every 1–2 weeks. Ipamorelin and hexarelin were given intravenously, hexarelin also subcutaneously, intranasally and by mouth; ibutamoren was taken as a tablet once a day. These are investigational regimens: the sources have no approved regimen for adults, and doses must not be chosen on one's own.
Who should see a doctor first
A doctor is needed before any experiments with these substances: in diabetes and blood sugar disorders (with ibutamoren glucose and HbA1c rose), in heart disease and heart failure, with swelling, in pituitary disease (the response to hexarelin in severe GH deficiency is minimal), in pregnancy. A child with slowed growth first needs the cause diagnosed: treatment of GH deficiency is prescribed by an endocrinologist.
What studies showed
| What was studied | Who and how many | Result | Source |
|---|---|---|---|
| Sermorelin, children with GH deficiency, 1 year | 86 children (of 110), no control | Growth 4.1 → 7.2 cm/year over 12 months; good response in 74% by month 6; fasting glucose unchanged | Thorner M J Clin Endocrinol Metab 1996. PMID 8772599 |
| Sermorelin, age 55–71, 16 weeks | 19 people (10 women, 9 men) | IGF-1 higher by week 2, close to baseline again by week 16; lean mass higher in men; sleep unchanged | Khorram O J Clin Endocrinol Metab 1997. PMID 9141536 |
| Sermorelin, men aged 64–76, 6 weeks | 11 men, no control | Night-time GH higher; IGF-1, body composition, glucose unchanged; 2 of 6 strength tests better | Vittone J Metabolism 1997. PMID 9005976 |
| CJC-1295, healthy people aged 21–61 | two RCTs, number not given | GH 2–10 times higher for 6 days or more; IGF-1 1.5–3 times higher for 9–11 days | Teichman SL J Clin Endocrinol Metab 2006. PMID 16352683 |
| Ipamorelin, single dose | 8 men for each of 5 doses | One GH release, peak at about 40 minutes; half-life 2 h | Gobburu JV Pharm Res 1999. PMID 10496658 |
| Ipamorelin, bowel paralysis after surgery | 114 people, phase 2 RCT | 25.3 versus 32.6 h to solid food, p = 0.15, difference not significant | Beck DE Int J Colorectal Dis 2014. PMID 25331030 |
| Hexarelin, GH and stress hormones by age | 60 people | In older people GH is half as high (951.1 versus 1829.7 µg·min/L, or ng·min/mL); prolactin, ACTH, cortisol rise | Arvat E Eur J Endocrinol 1997. PMID 9437229 |
| Hexarelin and the heart, healthy | 7 men | LVEF 64.0 → 70.7% after one injection; recombinant GH no effect | Bisi G J Endocrinol Invest 1999. PMID 10342360 |
| Hexarelin in cardiomyopathies | 8 dilated, 5 ischemic | Ischemic: LVEF 22.6 → 26.2%; dilated: no change | Imazio M Eur J Heart Fail 2002. PMID 11959048 |
| Ibutamoren, age 60–81, 1 year | 65 people (43 and 22), RCT | Lean mass +1.1 versus −0.5 kg; fat and strength unchanged; glucose +0.3 mmol/L (5 mg/dL) | Nass R Ann Intern Med 2008. PMID 18981485 |
| Ibutamoren after hip fracture, 24 weeks | 123 people, RCT | IGF-1 +51.4 ng/mL (+6.7 nmol/L); function mostly unchanged; stopped because of a heart failure signal | Adunsky A Arch Gerontol Geriatr 2011. PMID 21067829 |
Summary
Growth hormone peptides do one thing: they prompt the pituitary to release more of its own GH, and with CJC-1295 and ibutamoren IGF-1 rises after it. The best data are for sermorelin in GH deficiency in children; in adults hormone shifts have been shown, not a confirmed effect on strength, fat or sleep. If interest in the topic comes from tiredness, weight or age-related changes, it is worth starting with the causes and tests: these can be reviewed at a consultation.
Source: Growth hormone peptides: sermorelin, CJC-1295, ipamorelin, hexarelin — universum.earth. Dr. Pereligyn.
